Dazu gelesen
Brean Capital reiterated their buy rating on shares of Progenics Pharmaceuticals (NASDAQ:PGNX) in a research note released on Monday morning. They currently have a $11.00 target price on the stock.
Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) traded up 1.60% on Monday, hitting $6.35. The stock had a trading volume of 71,596 shares. Progenics Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $7.84. The company has a market cap of $441.88 million and a P/E ratio of 105.83.